NASDAQ:TCRR - Tcr2 Therapeutics Stock Price, Forecast & News

Tcr2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCRR stock has decreased by 23.3% and is now trading at $6.58. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tcr2 Therapeutics.

Tcr2 Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 6th 2020. View our earnings forecast for Tcr2 Therapeutics.

Tcr2 Therapeutics Inc (NASDAQ:TCRR) announced its quarterly earnings data on Monday, March, 30th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.10. View Tcr2 Therapeutics' earnings history.

2 brokerages have issued 1 year target prices for Tcr2 Therapeutics' stock. Their forecasts range from $16.00 to $19.00. On average, they expect Tcr2 Therapeutics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 166.0% from the stock's current price. View analysts' price targets for Tcr2 Therapeutics.

Media headlines about TCRR stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tcr2 Therapeutics earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutTcr2 Therapeutics.

Tcr2 Therapeutics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 801,100 shares, a drop of 8.4% from the February 27th total of 875,000 shares. Based on an average daily trading volume, of 77,700 shares, the days-to-cover ratio is presently 10.3 days. Currently, 6.8% of the shares of the stock are short sold. View Tcr2 Therapeutics' Current Options Chain.

Some companies that are related to Tcr2 Therapeutics include Translate Bio (TBIO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), GENFIT S A/ADR (GNFT), BAVARIAN NORDIC/S (BVNRY), Avrobio (AVRO), Atara Biotherapeutics (ATRA), Compugen (CGEN), Proteon Therapeutics (PRTO), MeiraGTx (MGTX), Aptose Biosciences (APTO), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), Vericel (VCEL) and Scholar Rock (SRRK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Exxon Mobil (XOM), Harpoon Therapeutics (HARP), II-VI (IIVI) and Novavax (NVAX).

(TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCRR stock can currently be purchased for approximately $6.58.

Tcr2 Therapeutics has a market capitalization of $158.42 million. The company earns $-24,250,000.00 in net income (profit) each year or ($98.53) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe. View additional information about Tcr2 Therapeutics.

The official website for Tcr2 Therapeutics is http://www.tcr2.com/.

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]